17,099 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 17,099 shares of the biopharmaceutical company’s stock, valued at approximately $1,251,000.

A number of other hedge funds have also modified their holdings of ITCI. CANADA LIFE ASSURANCE Co raised its stake in Intra-Cellular Therapies by 106.0% during the first quarter. CANADA LIFE ASSURANCE Co now owns 17,023 shares of the biopharmaceutical company’s stock worth $1,178,000 after acquiring an additional 8,760 shares in the last quarter. Tidal Investments LLC increased its position in shares of Intra-Cellular Therapies by 13.9% during the 1st quarter. Tidal Investments LLC now owns 3,698 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 450 shares in the last quarter. Farallon Capital Management LLC bought a new position in Intra-Cellular Therapies during the 1st quarter valued at about $15,985,000. First Hawaiian Bank boosted its position in Intra-Cellular Therapies by 8.3% in the second quarter. First Hawaiian Bank now owns 6,466 shares of the biopharmaceutical company’s stock valued at $443,000 after buying an additional 493 shares in the last quarter. Finally, DNB Asset Management AS grew its stake in Intra-Cellular Therapies by 20.1% during the second quarter. DNB Asset Management AS now owns 80,155 shares of the biopharmaceutical company’s stock worth $5,484,000 after buying an additional 13,402 shares during the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

ITCI stock opened at $86.43 on Wednesday. The stock has a market cap of $9.16 billion, a price-to-earnings ratio of -99.34 and a beta of 0.97. The company has a fifty day moving average price of $79.45 and a two-hundred day moving average price of $74.98. Intra-Cellular Therapies, Inc. has a one year low of $58.14 and a one year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.25) EPS. Research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. UBS Group reduced their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Morgan Stanley increased their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Needham & Company LLC restated a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group dropped their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has an average rating of “Moderate Buy” and a consensus target price of $97.23.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 34,396 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $77,962,764.36. This trade represents a 3.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.